Skip to content
  • About
  • Our Story
  • Network
  • Insights
  • About
  • Our Story
  • Network
  • Insights

From Cocktail Napkin to Global Platform: Fastcase-vLex, and Clio Unite to Democratize the Law

NYSE CIRCLE IPO Banner

Spencer Trask & Co. Nets Public Stake in Circle Internet Group at NYSE Debut

Food is Medicine

Vesselon Discovery Protects and Expands Drug Franchises

Spencer Trask & Co. Venture Fastcase Merges with Legal Intelligence Platform vLex

Lessons from the Collapse of SVB: Why Proper Risk Management and Transparency are Essential in the Financial Industry

Fraudster Sam Bankman-Fried is a Pathetic Character and a Product of our Time

Investor Insights: Part Two

Investor Insights: Part One

The Genome Makes Us Human

Business Development: What it Means for Your Business

A Message from Spencer Trask CEO, Bill Clifford: Respect the Individual Employee as Never Before

Bouncing Back from COVID-19: How Lessons Learned from Past Public Crises May Be Applied to the Challenges of Today

There is No Post-COVID-19 Culture

Staying Alive Post Pandemic

Did COVID Disrupt Your Exit Plan? Here’s How to Get Back on Track

Interos Protects Supply Chains with the Trensant AI Platform

Interos: SolarWinds Attack Highlights Need for Supply Chain Paradigm Shift

The MSC: Regeneration Orchestrator

The Affordable Care Act: Twelve Years Later

Supply Chain Unicorn Built on Spencer Trask & Co. AI Venture

ST Announces Global Crowdsourcing Program for Polio Eradication

ST Backed Ultra Capital Draws New Capital

ST Supports 6th Annual World Polio Day

Firm Funded by ST Acquired by Circle

Trensant AI Acquired by Interos Solutions

ST and Affiliates Close Sale of ImThera

Chairman Gives Talk on Smartphone Origin

Spencer Trask - Our Legacy

ST Chairman at Mobile World Congress

DLF to Honor Spencer Trask & CO. Chairman

ST Recognizes 100 Year Anniversary

X-twitter Linkedin
  • About
  • Our Story
  • Network
  • Insights
  • About
  • Our Story
  • Network
  • Insights
Contact

1-(800)-622-7078

[email protected]

The Immune Response Corporation

Revolution in Immunotherapy

DISCOVERY – Non-infectious viral vaccines.

INNOVATOR – In the history of medicine, few figures have had as profound an impact on human health and wellbeing as Dr. Jonas Salk. His polio vaccine breakthrough was the culmination of centuries of research, dating back to Louis Pasteur discovering inoculation. However, Salk’s method was different. He found a way to protect people from viruses without giving them the very disease the vaccine was designed to prevent.

Using this no-infection method, Salk worked with Kevin Kimberlin of Spencer Trask to develop cancer vaccines and an immunotherapeutic to slow or prevent AIDS. They patented and conducted preclinical studies on a cancer vaccine that demonstrated a startling 90% protection against lethal malignancies. 

IMPACT – A fusion of dendritic cells and the cancer antigen, their technology formed the basis for the first FDA-approved cell-based immunotherapy. Over 40,000 men with metastatic castrate-resistant prostate cancer have received the treatment, and it appears especially effective for African-American men who receive a 48% improved survival benefit compared to white men.

The team and facility making this immunotherapy also made clinical and commercial supplies of the first approved gene therapy, the CAT-T drug Kymriah.

The first approved cell-base immunotherapy and gene therapy prompted the FDA Commissioner to say, “New technologies such as gene and cell therapies hold out the potential to transform medicine and create an inflection point in our ability to treat and even cure many intractable illnesses.”

The noninfectious vaccine approach developed by Jonas Salk eliminated polio from the developed countries, his flu vaccine mitigated the effects of influenza for the past 75 years, and finally, the cancer vaccine developed at his Immune Response Corporation led the way to gene, cell-based, and immune therapy innovations that will impact human health for generations. In summary, Salk released the last step in enabling the most important preventative medicine – non-infectious viral vaccination.